Variation in IFNL4 genotype and response to interferon-based therapy of hepatitis C in HIV-positive patients with acute and chronic hepatitis C

Krämer, Benjamina,*; Nischalke, Hans Dietera,*; Boesecke, Christopha; Ingiliz, Patrickb; Voigt, Estherc; Mauss, Stefand; Stellbrink, Hans-Jürgene; Baumgarten, Axelb; Rockstroh, Juergen K.a; Spengler, Ulricha; Nattermann, Jacoba

doi: 10.1097/01.aids.0000433234.78807.54
Research Letters

The IFNL4 ss469415590 polymorphism has recently be shown to better predict treatment response in chronic hepatitis than the IL28B rs12979860 variant. However, no data exist in patients with HIV/hepatitis C virus (HCV) coinfection. Analysing 206 HCV(+)/HIV(+) and 162 HCV(+)/HIV(−) patients, we found that compared with IL28B rs12979860, IFNL4 ss469415590 was strongly associated with response to interferon/ribavirin therapy in HCV(+)/HIV(−) individuals but not in HIV(+)/HCV(+) patients. Thus, effects of the IFNL4 variant may differ in HIV(+) and HIV(−) patients.

aDepartment of Internal Medicine I, German Center for Infection Research, University of Bonn, Bonn

bMedical Center for Infectious Diseases (MIB), Berlin

cPraxis am Ebertplatz, Cologne

dCenter for HIV and Hepatogastroenterology, Duesseldorf

eICH, Hamburg, Germany.

*Benjamin Krämer and Hans Dieter Nischalke contributed equally to the writing of this article.

Correspondence to Jacob Nattermann, MD, Department of Internal Medicine I, University of Bonn, Sigmund-Freud-Straße 25, D-53105 Bonn, Germany. Tel: +49 228 287 51416; fax: +49 228 287 51419; e-mail: jacob.nattermann@ukb.uni-bonn.de

© 2013 Lippincott Williams & Wilkins, Inc.